Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India

FDA delays Corcept’s hypertension drug, seeks more evidence

The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates